Customising the therapeutic response of signalling networks to promote antitumor responses by drug combinations [PDF]
Frontiers in Oncology, 2014 Drug resistance, de novo and acquired, pervades cellular signalling networks from one signalling motif to another as a result of cancer progression and/or drug intervention.
Alexey eGoltsov +4 more
doaj +5 more sources
Combination Drug Therapy in Refractory Epilepsy
Pediatric Neurology Briefs, 2012 Researchers from University of Washington, Seattle, WA analyzed the treatment records from 148 developmentally disabled adults with refractory epilepsy cared for in 2 state-run institutions.
J Gordon Millichap
doaj +4 more sources
Quantifying the pharmacology of antimalarial drug combination therapy [PDF]
Scientific Reports, 2016 AbstractMost current antimalarial drugs are combinations of an artemisinin plus a ‘partner’ drug from another class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs in treating human malaria infections.
Katherine Kay +2 more
openaire +6 more sources
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n ...
Soon-Jib Yoo +8 more
doaj +1 more source
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
Frontiers in Pharmacology, 2021 Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance.
Bui Thi Bich Hanh +7 more
doaj +1 more source
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [PDF]
Diabetes & Metabolism Journal, 2020 BackgroundThere is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy.
Jeong Mi Kim +12 more
doaj +1 more source
Basic principles of combination therapy: focus on drug-drug interaction
Кардиоваскулярная терапия и профилактика, 2021 The article is devoted to the issue of drug interactions in the combination regimens. Today, when drug therapy is the first-line approach for patients with noncommunicable diseases, and the world population ageing leads to an increase in the number of ...
S. Yu. Martsevich +2 more
doaj +1 more source
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming [PDF]
Diabetes & Metabolism Journal, 2020 The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%.
Soung Won Jeong
doaj +1 more source
MedComm – Biomaterials and Applications, 2023 Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect.
Jingqi Xin +3 more
doaj +1 more source
Metabolic Derangements with Anticonvulsants in Children with Generalised Tonic-clonic Epilepsy: A Cross-sectional Study [PDF]
Journal of Clinical and Diagnostic Research, 2023 Introduction: Epilepsy is one of the most prevalent noncommunicable neurologic conditions, accounting for significant disability and mortality. The effects of Antiepileptic Drugs (AEDs) on total cholesterol, triglycerides, High-Density Lipoprotein ...
Jyoti Sharma +3 more
doaj +1 more source